Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CERo Therapeutics Holdings Inc (CEROW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: CEROW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.67% | Avg. Invested days 12 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.43 | 52 Weeks Range 0.00 - 0.04 | Updated Date 06/13/2025 |
52 Weeks Range 0.00 - 0.04 | Updated Date 06/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -122.86% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 317536 |
Shares Outstanding - | Shares Floating 317536 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
CERo Therapeutics Holdings Inc
Company Overview
History and Background
CERo Therapeutics Holdings Inc. is a preclinical stage biotechnology company focused on developing novel cell therapies for cancer. It was incorporated in 2021 and is working on preclinical development, which means it is a relatively new company.
Core Business Areas
- Cell Therapy Development: Developing cell therapies targeting solid tumors.
Leadership and Structure
The company has a management team focused on preclinical research and development. Organizational structure follows typical biotechnology company structure focused on clinical development.
Top Products and Market Share
Key Offerings
- CER-123 Cell Therapy: Preclinical stage cell therapy targeting solid tumors. No current market share or revenue. Competitors include larger cell therapy companies focused on solid tumor treatments.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in genetic engineering and immunotherapy. There's a growing focus on solid tumor treatments.
Positioning
CERo Therapeutics is positioned as a preclinical stage company with a novel approach to cell therapy for solid tumors. Its competitive advantage lies in its specific technology, but it is behind in clinical development compared to more established companies.
Total Addressable Market (TAM)
The global cell therapy market is estimated to reach hundreds of billions by 2030. Cero Therapeutics is targeting a segment of this market focused on solid tumors. TAM values are difficult to quantify due to the company's early stage.
Upturn SWOT Analysis
Strengths
- Novel cell therapy approach
- Experienced management team in research
- Intellectual property protection
Weaknesses
- Preclinical stage - high risk
- Limited financial resources
- Small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion of product pipeline
Threats
- Competition from established cell therapy companies
- Regulatory hurdles
- Clinical trial failures
- Financing risks
Competitors and Market Share
Key Competitors
- BMY
- GILD
- BLUE
Competitive Landscape
CERo Therapeutics faces significant competition from larger, more established companies with approved cell therapy products. Its success depends on demonstrating superior efficacy and safety in its clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable at this stage of the company.
Future Projections: Future growth depends on clinical trial results and regulatory approvals. Analyst estimates would be highly speculative at this point.
Recent Initiatives: Focus is on advancing CER-123 into clinical trials.
Summary
CERo Therapeutics is a preclinical stage biotechnology company with a novel approach to cell therapy for solid tumors. Its success hinges on positive clinical trial results and securing funding. The company faces competition from larger, more established companies and the inherent risks associated with drug development. The company's innovative technology and dedicated management present some strengths, but its lack of revenue and early development stage represent significant weaknesses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may be subject to change. Investment in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-11-29 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.